STTK Jun 2024 7.500 call
- GlobeNewswire
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress
– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients to hematopoietic cell transplantation – – SL-172154 continued to demonstrate an acceptable safety profile in combination with AZA – – EHA poster presentation to include additional data from the next planned data cutoff in the second quarter of 2024 – AUSTIN, TX and DURHAM, NC, May 14, 2024 (GLOBE NEWS
- Zacks
What Makes Shattuck Labs (STTK) a New Buy Stock
Shattuck Labs (STTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks
Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Shattuck Labs (STTK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
